Y-mAbs Therapeutics (YMAB) Misses Q4 EPS by 58c

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q4 EPS of ($1.28), $0.58 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $9.6 million versus the consensus estimate of $10.82 million.

The Company had approximately $181.6 million in cash and cash equivalents as of December 31, 2021.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Espey Manufacturing (ESP) Tops Q4 EPS by 24c
• KB Home (KBH) PT Lowered to $50 at RBC Capital